• 1
    Berke G. The binding and lysis of target cells by cytotoxic lymphocytes: molecular and cellular aspects. Ann Rev Immunol 1994; 12:73573.
  • 2
    Schuler T, Qin Z, Ibe S, Noben-Trauth N, Blankenstein T. T helper cell type 1-associated and cytotoxic T lymphocyte-mediated tumor immunity is impaired in interleukin 4-deficient mice. J Exp Med 1999; 189:80310.
  • 3
    Abe K, Harada M, Tamada K, Ito O, Li T, Nomoto K. Early-appearing tumor-infiltrating natural killer cells play an important role in the nitric oxide production of tumor-associated macrophages through their interferon production. Cancer Immunol Immunother 1998; 45:22533.DOI: 10.1007/s002620050437
  • 4
    Levitsky HI, Lazenby A, Hayashi RJ, Pardoll DM. In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med 1994; 179:121524.
  • 5
    Maeda H & Shiraishi A. TGF-β contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice. J Immunol 1996; 156:738.
  • 6
    Maeda H, Kuwahara H, Ichimura Y, Ohtsuki M, Kurakata S, Shiraishi A. TGF-β enhances macrophage ability to produce IL-10 in normal and tumor-bearing mice. J Immunol 1995; 155:492632.
  • 7
    Yamamoto N, Zou JP, Li XF et al. Regulatory mechanisms for production of IFN-γ and TNF by antitumor T cells or macrophages in the tumor-bearing state. J Immunol 1995; 154:228190.
  • 8
    Kondo S, Asano M, Matsuo K, Ohmori I, Suzuki H. Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients. Biochim Biophys Acta 1994; 122:2114.
  • 9
    Faust A, Rothe H, Schade U, Lampeter E, Kolb H. Primary nonfunction of islet grafts in autoimmune diabetic nonobese diabetic mice is prevented by treatment with interleukin-4 and interleukin-10. Transplantation 1996; 62:64852.
  • 10
    Kundu N & Fulton AM. Interleukin-10 inhibits tumor metastasis, downregulates MHC class I, and enhances NK lysis. Cell Immunol 1997; 180:5561.DOI: 10.1006/cimm.1997.1176
  • 11
    Tada T, Ohzeki S, Utsumi K et al. Transforming growth factor-β-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. J Immunol 1991; 146:107782.
  • 12
    Chen W, Jin W, Wahl SM. Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor beta (TGF-beta) production by murine CD4 (+) T cells. J Exp Med 1998; 188:184957.
  • 13
    Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, De Vries JE, Roncarolo MG. A CD4+ T cells subset inhibits antigen-specific T cell responses and prevents colitis. Nature 1997; 389:73742.DOI: 10.1038/39614
  • 14
    Neurath MF, Fuss I, Kelsall BL, Presky DH, Waegell W, Strober W. Experimental granulomatous colitis in mice is abrogated by induction of TGF-β-mediated oral tolerance. J Exp Med 1996; 183:260516.
  • 15
    Inobe J, Slavin AJ, Komagata Y, Chen Y, Liu L, Weiner HL. IL-4 is a differentiation factor for transforming growth factor-beta secreting Th3 cells and oral administration of IL-4 enhances oral tolerance in experimental allergic encephalomyelitis. Eur J Immunol 1998; 28:278090.DOI: 10.1002/(sici)1521-4141(199809)28:09<2780::aid-immu2780>;2-a
  • 16
    Cobbold S & Waldmann H. Infectious tolerance. Curr Opin Immunol 1998; 10:51824.
  • 17
    Rizzo LV, Morawetz RA, Miller-Rivero NE et al. IL-4 and IL-10 are both required for the induction of oral tolerance. J Immunol 1999; 162:261322.
  • 18
    Kawakami Y, Robbins PF, Wang X et al. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles. J Immunol 1998; 161:698592.
  • 19
    Mao XW, Kettering JD, Gridley DS. Immunotherapy with low-dose interleukin-2 and anti-transforming growth factor-β antibody in a murine tumor model. Cancer Biother 1994; 9:31727.
  • 20
    Gridley DS, Sura SS, Uhm JR, Lin CH, Kettering JD. Effects of anti-transforming growth factor-β antibody and interleukin-2 in tumor-bearing mice. Cancer Biother 1993; 8:15970.
  • 21
    Dunn PL & North RJ. Effect of advanced ageing on ability of mice to cause regression of an immunogenic lymphoma in response to immunotherapy based on depletion of suppressor T cells. Cancer Immunol Immunother 1991; 33:4213.
  • 22
    Seo N & Egawa K. Suppression of cytotoxic T lymphocyte activity by γ/δ T cells in tumor-bearing mice. Cancer Immunol Immunother 1995; 40:35866.DOI: 10.1007/s002620050185
  • 23
    Seo N, Tokura Y, Furukawa F, Takigawa M. Down-regulation of tumoricidal NK and NK T cell activities by MHC Kb molecules expressed on Th2-type γδ T and αβ T cells co-infiltrating in early B16 melanoma lesions. J Immunol 1998; 161:413845.
  • 24
    Seo N, Tokura Y, Takigawa M, Egawa K. Depletion of IL-10- and TGF-β-producing regulatory γδ T cells by administered a daunomycin-conjugated specific monoclonal antibody in early tumor lesions augments the activity of CTLs and NK cells. J Immunol 1999; 163:2429.
  • 25
    Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, Muramatsu S, Steinman RM. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992; 176:1693702.
  • 26
    Zhang Y, Mukaida N, Wang J, Harada A, Akiyama M, Matsushima K. Induction of dendritic cell differentiation by granulocyte-macrophage colony-stimulating factor, stem cell factor, and tumor necrosis factor αin vitro from lineage phenotype-negative c-kit+ murine hematopoietic progenitor cells. Blood 1997; 90:484253.
  • 27
    Maraskovsky E, Troutt AB, Kelso A. Co-engagement of CD3 with LFA-1 or ICAM-1 adhesion molecules enhances the frequency of activation of single murine CD4+ and CD8+ T cells and induces the synthesis of IL-3 and IFN-γ but not IL-4 or IL-6. Int Immunol 1992; 4:47585.
  • 28
    Enk AH & Katz SI. Identification and induction of keratinocyte-derived IL-10. J Immunol 1992; 149:925.
  • 29
    Rugo HS, O'Hanley P, Bishop AG, Pearce MK, Abrams JS, Howard M, O'Garra A. Local cytokine production in a murine model of Escherichia coli pyelonephritis. J Clin Invest 1992; 89:10329.
  • 30
    Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999; 59:312833.
  • 31
    Seo N & Tokura Y. Down-regulation of innate and acquired anti-tumor immunity by bystander γδ and αβ T lymphocytes with Th2 or Tr1 cytokine profiles. J Interferon Cytokine Res 1999; 19:55561.DOI: 10.1089/107999099313686
  • 32
    Mocci S, Dalrymple SA, Nishinakamura R, Murray R. The cytokine stew and innate resistance to L. monocytogenes. Immunol Rev 1997; 158:10714.
  • 33
    Letterio JJ & Roberts AB. Regulation of immune responses by TGF-β. Annu Rev Immunol 1998; 16:13761.
  • 34
    Rocken M, Urban J, Shevach EM. Antigen-specific activation, tolerization, and reactivation of the interleukin 4 pathway in vivo. J Exp Med 1994; 179:188593.
  • 35
    Asano M, Toda M, Sakaguchi N, Sakaguchi S. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med 1996; 184:38796.
  • 36
    Flad T, Spengler B, Kalbacher H et al. Direct identification of major histocompatibility complex class I-bound tumor-associated peptide antigens of a renal carcinoma cell line by a novel mass spectrometric method. Cancer Res 1998; 58:580311.
  • 37
    Boon T, Cerottini JC, Van den Eynde B, Van Der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994; 12:33765.